Programmed death-ligand 1 (PD-L1) is an immune-related biomarker that can be expressed on the surface of many tissue types, including tumor cells. It helps keep your immune system from attacking healthy tissue by acting as a kind of. KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with non–small cell lung cancer (NSCLC) expressing programmed death ligand 1 (PD-L1) [tumor proportion score (TPS) ≥1%] as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or. at specific subtype of cancer you have. Cancer biomarkers are often referred to by a 3- or 4-l tter abbreviation, such as ALK or PD-L1. If you have advanced non-sm tested positive for the PD-L1 biomarker. It is. In summary, PDL is an abbreviation that can stand for various terms depending on the context, and its interpretation can vary across different fields such as technology, business, education, geography, government, law and other specialized areas.
[PDF Version]